CN107789322B - 一种沃尼妙林预混剂及其制备方法与应用 - Google Patents
一种沃尼妙林预混剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN107789322B CN107789322B CN201711047939.3A CN201711047939A CN107789322B CN 107789322 B CN107789322 B CN 107789322B CN 201711047939 A CN201711047939 A CN 201711047939A CN 107789322 B CN107789322 B CN 107789322B
- Authority
- CN
- China
- Prior art keywords
- valnemulin
- powder
- parts
- premix
- wheat bran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 title claims abstract description 100
- 229950008166 valnemulin Drugs 0.000 title claims abstract description 100
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 30
- MFBPRQKHDIVLOJ-AFFLPQGKSA-N 133868-46-9 Chemical compound Cl.CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 MFBPRQKHDIVLOJ-AFFLPQGKSA-N 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 239000003085 diluting agent Substances 0.000 claims abstract description 19
- 239000003463 adsorbent Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000011230 binding agent Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 238000007873 sieving Methods 0.000 claims abstract description 9
- 208000006673 asthma Diseases 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 6
- 208000001848 dysentery Diseases 0.000 claims abstract description 6
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 6
- 208000021760 high fever Diseases 0.000 claims abstract description 5
- 238000010298 pulverizing process Methods 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 92
- 235000015099 wheat brans Nutrition 0.000 claims description 27
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 229930006000 Sucrose Natural products 0.000 claims description 20
- 239000005720 sucrose Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 241000209094 Oryza Species 0.000 claims description 15
- 235000007164 Oryza sativa Nutrition 0.000 claims description 15
- 235000009566 rice Nutrition 0.000 claims description 15
- 239000000853 adhesive Substances 0.000 claims description 14
- 230000001070 adhesive effect Effects 0.000 claims description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- 229920003081 Povidone K 30 Polymers 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 8
- 229940063655 aluminum stearate Drugs 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- 235000019737 Animal fat Nutrition 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 244000144977 poultry Species 0.000 claims description 7
- 244000144972 livestock Species 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 229940126678 chinese medicines Drugs 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 52
- 241000282887 Suidae Species 0.000 abstract description 18
- 241000282898 Sus scrofa Species 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 206010011224 Cough Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 1
- 238000004537 pulping Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 27
- 239000013641 positive control Substances 0.000 description 16
- 239000013642 negative control Substances 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 12
- 239000000428 dust Substances 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 238000013441 quality evaluation Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 3
- 229960004885 tiamulin Drugs 0.000 description 3
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 241001148552 Mycoplasma canis Species 0.000 description 1
- 241001468278 Mycoplasma felis Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZRZNJUXESFHSIO-UHFFFAOYSA-N Pleuromutilin Natural products CC1C(O)C(C)(C=C)CC(OC(=O)CO)C2(C)C(C)CCC31C2C(=O)CC3 ZRZNJUXESFHSIO-UHFFFAOYSA-N 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 bitter taste Chemical compound 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- ZRZNJUXESFHSIO-VYTKZBNOSA-N pleuromutilin Chemical compound C([C@H]([C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CO)C)C[C@]32[C@H]1C(=O)CC3 ZRZNJUXESFHSIO-VYTKZBNOSA-N 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 238000009700 powder processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
Abstract
Description
分组 | 病例数 | 痊愈(%) | 有效(%) | 无效(%) |
阴性对照组 | 30 | 0 | 0 | 100 |
阳性对照组 | 30 | 63.3 | 26.7 | 10.0 |
试验组 | 30 | 96.7 | 0 | 3.3 |
分组 | 病例数 | 优(%) | 良(%) | 无效(%) |
试验组 | 22 | 95.5 | 4.5 | 0 |
阳性对照组 | 22 | 68.2 | 22.7 | 9.1 |
阴性对照组 | 22 | 0 | 0 | 100 |
分组 | 病例数 | 痊愈(%) | 有效(%) | 无效(%) |
试验组 | 20 | 85.0 | 15.0 | 5.0 |
阳性对照组 | 20 | 65.0 | 10.0 | 15.0 |
阴性对照组 | 20 | 0 | 0 | 100.0 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711047939.3A CN107789322B (zh) | 2017-10-31 | 2017-10-31 | 一种沃尼妙林预混剂及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711047939.3A CN107789322B (zh) | 2017-10-31 | 2017-10-31 | 一种沃尼妙林预混剂及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107789322A CN107789322A (zh) | 2018-03-13 |
CN107789322B true CN107789322B (zh) | 2020-05-15 |
Family
ID=61548807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711047939.3A Active CN107789322B (zh) | 2017-10-31 | 2017-10-31 | 一种沃尼妙林预混剂及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107789322B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101601658A (zh) * | 2009-07-10 | 2009-12-16 | 河北远征药业有限公司 | 盐酸沃尼妙林包衣颗粒的制备方法 |
CN102406618A (zh) * | 2011-09-30 | 2012-04-11 | 上海恒丰强动物药业有限公司 | 盐酸沃尼妙林颗粒剂及其制备方法 |
CN102813629A (zh) * | 2012-08-29 | 2012-12-12 | 湖北龙翔药业有限公司 | 一种酒石酸沃尼妙林预混剂的制备方法 |
CN103751092A (zh) * | 2013-12-30 | 2014-04-30 | 华南农业大学 | 一种盐酸沃尼妙林肠溶性固体分散体及其制备方法与应用 |
CN104784411A (zh) * | 2014-01-17 | 2015-07-22 | 北京大北农动物保健科技有限责任公司 | 用于防治猪呼吸道疾病的药物组合物、预混料及配合料 |
-
2017
- 2017-10-31 CN CN201711047939.3A patent/CN107789322B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101601658A (zh) * | 2009-07-10 | 2009-12-16 | 河北远征药业有限公司 | 盐酸沃尼妙林包衣颗粒的制备方法 |
CN102406618A (zh) * | 2011-09-30 | 2012-04-11 | 上海恒丰强动物药业有限公司 | 盐酸沃尼妙林颗粒剂及其制备方法 |
CN102813629A (zh) * | 2012-08-29 | 2012-12-12 | 湖北龙翔药业有限公司 | 一种酒石酸沃尼妙林预混剂的制备方法 |
CN103751092A (zh) * | 2013-12-30 | 2014-04-30 | 华南农业大学 | 一种盐酸沃尼妙林肠溶性固体分散体及其制备方法与应用 |
CN104784411A (zh) * | 2014-01-17 | 2015-07-22 | 北京大北农动物保健科技有限责任公司 | 用于防治猪呼吸道疾病的药物组合物、预混料及配合料 |
Also Published As
Publication number | Publication date |
---|---|
CN107789322A (zh) | 2018-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103830187B (zh) | 一种替米考星固体分散颗粒及其制备方法和应用 | |
CN104586774B (zh) | 一种替米考星微丸的制备工艺 | |
CN103054808B (zh) | 一种替米考星干混悬剂及其制备方法和用途 | |
CN105726487B (zh) | 一种高含量阿莫西林可溶性粉剂制备方法及应用 | |
CN103948656B (zh) | 一种含穿心莲和磷霉素的畜禽用复方药物 | |
CN107753437B (zh) | 一种替米考星预混剂及其制备方法与应用 | |
CN103536536B (zh) | 一种氟苯尼考组合物可湿性固体分散粉及其制备方法 | |
CN104800167A (zh) | 一种氟苯尼考可溶性粉及其制备方法 | |
CN107789322B (zh) | 一种沃尼妙林预混剂及其制备方法与应用 | |
CN100337622C (zh) | 一种含延胡索酸泰妙菌素的固体分散体及制备方法 | |
CN107693495B (zh) | 一种泰妙菌素预混剂及其制备工艺与应用 | |
CN107595871A (zh) | 含伊维菌素复方制剂及其制备方法 | |
CN107550867B (zh) | 一种抗静电酒石酸泰万菌素预混剂及其制备方法 | |
CN104586875B (zh) | 复方替米考星肠溶颗粒的制备方法 | |
CN106620668A (zh) | 一种复方替米考星固体分散剂及其制备方法 | |
CN104161761B (zh) | 一种复方土霉素注射液及其制备方法 | |
CN102698244B (zh) | 一种防治仔猪腹泻和促进仔猪生长的药物组合物 | |
CN112843011B (zh) | 一种替米考星预混剂及其制备方法 | |
CN105796504B (zh) | 一种盐酸沃尼妙林缓释颗粒及其制备方法和应用 | |
CN107595785B (zh) | 一种泰乐菌素预混剂及其制备方法与应用 | |
CN107753436B (zh) | 一种泰万菌素预混剂及其制备方法与应用 | |
CN113332247A (zh) | 一种盐酸金霉素可溶性粉及其制备方法和应用 | |
CN104473958A (zh) | 一种复方预混剂及其制备方法和应用 | |
CN104127429A (zh) | 一种用于防治畜禽呼吸道疾病的饮水剂及其制备方法 | |
Yousef et al. | Effect of Mustard, Onion and Probiotic on the Growth Performance and Immune Status of Oreochromis Niloticus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201207 Address after: 271000 Fangcun Town, Daiyue district, Tai'an City, Shandong Province Patentee after: SHANDONG ZHONGNONGPUNING PHARMACEUTICAL Co.,Ltd. Address before: 611130, Chengdu District, Sichuan City, Wenjiang province science and Technology Industrial Development Zone on both sides of the road, Golden House Road Patentee before: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A warnemolin premix and its preparation method and Application Effective date of registration: 20220426 Granted publication date: 20200515 Pledgee: Taian Bank Co.,Ltd. Daizong sub branch Pledgor: SHANDONG ZHONGNONGPUNING PHARMACEUTICAL CO.,LTD. Registration number: Y2022980004694 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230710 Granted publication date: 20200515 Pledgee: Taian Bank Co.,Ltd. Daizong sub branch Pledgor: SHANDONG ZHONGNONGPUNING PHARMACEUTICAL CO.,LTD. Registration number: Y2022980004694 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Vanimulin Premix and Its Preparation Method and Application Effective date of registration: 20230808 Granted publication date: 20200515 Pledgee: Taian Bank Co.,Ltd. Daizong sub branch Pledgor: SHANDONG ZHONGNONGPUNING PHARMACEUTICAL CO.,LTD. Registration number: Y2023980051285 |